Received Mar 24, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | UNK | Unknown | PO / MO |
The patient took oral typhoid vaccine not in recommended way (two doses 25 hours apart instead of skipping the day in between); Case reference number US-BN-2024-002626 is a spontaneous case initially received from other healthcare professional via Med Communications (reference number: USBAV24-2655) on 08-Oct-2024 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On an unspecified date, the patient took a dose of Vivotif (batch number: unknown), at an unknown dose, orally, for unknown indication. On unspecified date, reported as 25 hours apart instead of skipping the day in between the doses, patient took the next dose of Vivotif (batch number: unknown), at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administration'). At the time of the initial report, it was unknown if the patient experienced any adverse event due to the Vivotif vaccination. Non-significant follow-up was downloaded from VAERS on 09-May-2025 included new reference number. Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20241008-f13c04 to US-BAVARIAN NORDIC A/S-US-BN-2024-002626, in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A female patient of unspecified age took the next dose of Vivotif, at an unknown dose, orally, 25 hours apart instead of skipping the day in between the doses which is considered as inappropriate schedule of vaccine administration. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to the Vivotif vaccination. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age took the next dose of Vivotif, at an unknown dose, orally, 25 hours apart instead of skipping the day in between the doses which is considered as inappropriate schedule of vaccine administration. Inappropriate schedule of product administration is considered listed per company convention. At this point, it was unknown if the patient experienced any adverse event due to the Vivotif vaccination. The patient's medical history and concomitant medication details were not provided. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: None